uniQure N.V. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
uniQure N.V. (QURE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 1.44% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2021-03-01
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-03-31 was 2.87%.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-06-30 was 3.07%.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-09-30 was 2.48%, a 31.22% increase year-over-year.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-03-31 was 2.70%.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 1.44%, a 49.83% decline from fiscal 2019.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 2.87%, a 10.31% decline from fiscal 2018.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 3.20%, a 13.88% increase from fiscal 2017.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.81%, a 5.24% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2020-12-31 | 1.44% 10-K · filed 2021-03-01 | |||
| 2019-12-31 | 2.87% 10-K · filed 2021-03-01 | |||
| 2019-03-31 | 2.87% 10-Q · filed 2020-04-29 | |||
| 2018-12-31 | 3.20% 10-K · filed 2021-03-01 | |||
| 2018-09-30 | 3.10% 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | 3.07% 10-Q · filed 2018-08-08 | 3.07% 10-Q · filed 2018-08-08 | ||
| 2017-12-31 | 2.81% 10-K · filed 2020-03-02 | |||
| 2017-09-30 | 2.48% 10-Q · filed 2017-11-01 | 2.81% 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | 2.81% 10-Q · filed 2018-08-08 | |||
| 2017-03-31 | 2.70% 10-Q · filed 2018-04-30 | |||
| 2016-12-31 | 2.67% 10-K · filed 2019-02-28 | |||
| 2016-09-30 | 1.89% 10-Q · filed 2017-11-01 | 1.96% 10-Q · filed 2017-11-01 | ||
| 2015-12-31 | 0.62% 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |